PP22 Thyroid Neoplasia

Program: Abstracts - Orals, Poster Previews, and Posters
Poster Session
Thyroid/HPT Axis-Basic
Saturday, April 2, 2016: 11:30 AM-11:45 AM
Room 210 (BCEC)
Chairs:
Jennifer Anne Sipos, MD, The Ohio State University Wexner Medical Center, Columbus, OH and Electron Kebebew, M.D., National Cancer Institute, NIH, Bethesda, MD

Nothing to Disclose: JAS, EK Disclosure Not Provided: ALM
Shirin Haddady, MD MPH, Medicine, Division of Endocrinology, Diabetes and Weight Management, Boston University Medical School, Boston, Leena Shahla, MD, Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Massachusetts Medical School, Worcester, MA, Mira Sofia Tiglao Torres, MD, Endocrinology and Diabetes, University of Massachusetts, Worcester, MA and Marjorie Safran, MD, Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Massachusetts Medical School, Pittsfield, MA
Poster Board Number: SAT 279
Seong-Keun Yoo1, Seungbok Lee1, Su-jin Kim2, Hyeon-Gun Jee3, Kyu Eun Lee2 and Jeong-Sun Seo1, (1)Genomic Medicine Institute, Seoul, South Korea
(2)Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
(3)Research Institute, National Medical Center, Seoul, South Korea
Poster Board Number: SAT 286
Jian Yu Xu, MD, PhD1, Tanweer Zaidi, MD2, Gilbert J Cote, PHD1, Mimi I-Nan Hu, MD1, Steven G Waguespack, MD1, Maria E Cabanillas, MD1, Anita K Ying, MD1, Naifa L Busaidy, MD3, Mouhammed Amir Habra, MD1, Namita Shanbhag, MS2, Duy Truong, BS4, Robert K. Yu, MS5, Sanjay Shete, PhD5, Ruth L. Katz, MD2 and Steven I Sherman, MD6, (1)Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
(2)PATHOLOGY, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TX
(3)Departments of endocrine neoplasia and hormonal disorders, MD Anderson Cancer Center, Houston, TX
(4)PATHOLOGY, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
(5)BIOSTATISTICS, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TX
(6)Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine,, The University of Texas MD Anderson Cancer Center, Houston, TX
Poster Board Number: SAT 300
Shih-Min Cheng, PhD1, Kevin Qu1, Cindy Barlan1, Hai-rong Li1, Jared F. Taylor1, Andrew Grupe, PhD2, David A. Wolfson2, Alla Smolgovsky2, Heather R. Sanders, PhD1, Anna Gerasimova, PhD1, Quoclinh Nguyen1, Joseph J. Catanese1, Charles M. Strom, MD, PhD1, Frederick K. Racke, MD, PhD1, Frederic M. Waldman, MD, PhD1, Richard E. Reitz, MD3 and Feras M. Hantash, PhD1, (1)Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
(2)Quest Diagnostics Nichols Institute, Alameda, CA
(3)Endocrinology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Poster Board Number: SAT 283

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire